Modalis gains foundational CRISPR IP access

By The Science Advisory Board staff writers

April 3, 2020 -- Modalis Therapeutics has licensed intellectual property (IP) from CRISPR-related gene-editing company Editas Medicine.

Through the agreement, Modalis will use CRISPR-Guide Nucleotide Directed Modulation (CRISPR-GNDM) technology to create gene therapies for patients with genetic disorders. Financial terms of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.